Business Context and Reporting Period
This Form 6-K, filed on April 28, 2023, incorporates a press release detailing RedHill Biopharma Ltd.'s financial results for the fourth quarter and full year ended December 31, 2022. RedHill is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. The reporting period marks a strategic pivot following the extinguishment of all debt obligations in exchange for the transfer of rights to its product Movantik to HealthCare Royalty (HCR). The company is now debt-free with a reduced cost base, focusing on commercial growth of Talicia and Aemcolo, and advancing its late-stage pipeline including opaganib and RHB-107.
Key Financial Metrics
| Metric | Q4 2022 | Q4 2021 | Full Year 2022 | Full Year 2021 |
|---|---|---|---|---|
| Net Revenues | $12.8 million | $22.1 million | $61.8 million | $85.8 million |
| Cost of Revenues | $8.6 million | $19.3 million | $33.3 million | $49.4 million |
| Gross Profit | $4.2 million | $2.7 million | $28.5 million | $36.4 million |
| Operating Loss | $9.9 million | $20.7 million | $42.8 million | $81.1 million |
| Net Loss | Filing text does not provide a clear Q4 value | Filing text does not provide a clear Q4 value | $71.7 million | $97.7 million |
| Cash Balance (Dec 31, 2022) | $36.1 million (including restricted cash) | |||
| Net Cash Used in Operating Activities | $2.4 million | $14.9 million | $29.2 million | $65.0 million |
Liquidity and Debt: As of December 31, 2022, the company held a cash balance of $36.1 million. On February 6, 2023, RedHill extinguished all debt obligations under its credit agreement with HCR in exchange for the transfer of Movantik rights. The company is currently debt-free.
Material Changes Versus Prior Period
- Revenue Decline: Net revenues decreased 42% in Q4 2022 and 28% for the full year 2022 compared to prior periods. This was primarily driven by increased gross-to-net allowances related to Movantik, despite prescription growth in Talicia and Movantik.
- Cost Reduction: Operating expenses were significantly reduced. R&D expenses dropped 81% in Q4 2022 and 75% for the full year, attributed to the completion of COVID-related clinical trials and cost optimization. Selling, Marketing, and General and Administrative (SG&A) expenses decreased 26% in Q4 and 27% for the full year due to cost-control measures and a reduced salesforce.
- Improved Operating Loss: The operating loss narrowed significantly, decreasing from $20.7 million in Q4 2021 to $9.9 million in Q4 2022, and from $81.1 million in 2021 to $42.8 million in 2022.
- Debt Extinguishment: A material change occurred post-period end (February 2023) where all debt was extinguished via the sale of Movantik, fundamentally altering the company's capital structure.
Guidance, Outlook, and Operational Highlights
Commercial Outlook: Management expects to maximize sales of Talicia and Aemcolo. Talicia demonstrated 57% year-over-year prescription growth in Q4 2022. The company launched a warranty program for Talicia to support patient access. Transition services revenue from HCR regarding Movantik is expected to add to revenue streams for up to 12 months.
Pipeline Catalysts:
- Opaganib: Selected by the NIH's Radiation and Nuclear Countermeasures Program (RNCP) for Acute Radiation Syndrome (ARS) testing. Received FDA guidance on the Animal Rule regulatory pathway, with potential for a Priority Review Voucher.
- RHB-102 (BEKINDA): Received positive scientific advice from the UK MHRA; a Marketing Authorisation Application (MAA) for oncology support is planned.
- RHB-107 (Upamostat): Positive Phase 2 data published for non-hospitalized COVID-19. Discussions are ongoing for external non-dilutive funding for Phase 3 development.
- RHB-204: Received USPTO Notice of Allowance for a patent covering pulmonary NTM disease treatment.
Risks and Contingencies: The company faces risks related to the success of clinical trials, regulatory approvals, and the ability to secure non-dilutive funding for pipeline advancement. There is also uncertainty regarding the continuation of prescription growth and the successful commercialization of new products.
Key Facts for Investor Verification
- Debt Status: Verify the final terms of the Movantik sale and the complete extinguishment of debt obligations with HCR as of February 2023.
- Cash Runway: Assess the $36.1 million cash balance against the reduced but ongoing operating burn rate to determine the runway for pipeline development.
- Talicia Growth Sustainability: Monitor whether the 57% year-over-year prescription growth for Talicia can be sustained given the competitive landscape and gross-to-net allowance pressures.
- Regulatory Milestones: Track the progress of the UK MAA submission for RHB-102 and the FDA Animal Rule pathway for opaganib, as these are critical value drivers.
- Funding for RHB-107: Confirm the status of discussions for external non-dilutive funding required for the Phase 3 COVID-19 study of RHB-107.